Skip to main content
. Author manuscript; available in PMC: 2019 Aug 9.
Published in final edited form as: Cancer Biol Ther. 2008 Aug 30;7(8):1212–1225. doi: 10.4161/cbt.7.8.6220

Figure 4.

Figure 4.

High expression of the breast CAF gene signature is associated with poor clinical outcome in breast cancer patients treated with tamoxifen monotherapy. (A) Venn diagrams summarizing how the two gene signatures were derived by comparing and intersecting the gene sets from matched NFs and CAFs from three different patients. (B) Gene expression data from 60 ER-positive human breast tumors that were both micro- and macrodissected were analyzed for the expression pattern of 118 genes upregulated in CAFs. A core of proliferation associated genes that are regulated by the RB/E2F pathway (marked in red) strongly co-segregated in this analyses. (C) A Kaplan-Meyer survival analysis was conducted, wherein the recurrence of those tumors in the highest quartile of overall expression was compared against the remainder of the cohort (p < 0.001). Patients in the High CAF gene expression group had a poor prognosis on Tamoxifen mono-therapy, with greater than a 3.8-fold reduction in recurrence-free survival.